SCHEMBL4936632

SCHEMBL4936632

CS(=O)(=O)N1CCC(NC(=O)c2nscc2NC(=O)c2c(Cl)cccc2Cl)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK14 O94921 15/20 0.46
CCNY Q8ND76 13/20 0.46
LMNA P02545 1/20 0.46
RAB9A P51151 1/20 0.46
CNR1 P21554 2/20 0.45
SMYD3 Q9H7B4 1/20 0.43
CCNT1 O60563 2/20 0.43
CDK9 P50750 2/20 0.43
CDK5 Q00535 2/20 0.43
CDK5R1 Q15078 2/20 0.43
CASK O14936 1/20 0.43
CDKL5 O76039 1/20 0.43
CCNB2 O95067 1/20 0.43
CDK1 P06493 1/20 0.43
CDK4 P11802 1/20 0.43
CCNB1 P14635 1/20 0.43
CCNA2 P20248 1/20 0.43
MAK P20794 1/20 0.43
CDK11B P21127 1/20 0.43
CCND1 P24385 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14114409 0.88 CDK5 (0.47) CDK14CCNYCCNT1CDK9CDK5
SCHEMBL2029686 0.83 CDK14 (0.48) CDK14CCNYLMNARAB9ACNR1
SCHEMBL23271141 0.81 CDK14 (0.71) CDK14CCNY
SCHEMBL17252164 0.79 CDK14 (0.70) CDK14CCNYCCNT1CDK9CDK5
SCHEMBL23270992 0.78 CDK14 (0.75) CDK14CCNYCDK2CDK16
SCHEMBL23270991 0.78 CDK14 (0.75) CDK14CCNYCDK2CDK16
SCHEMBL13993660 0.78 LMNA (0.46) CDK14CCNYLMNARAB9ACNR1
SCHEMBL8262596 0.77 CDK14 (0.43) CDK14CCNYLMNARAB9ACNR1
SCHEMBL8261492 0.77 CDK2 (0.49) CDK14CCNYLMNARAB9ACNR1
SCHEMBL8263999 0.77 CDK14 (0.52) CDK14CCNYLMNARAB9ACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US disclosed
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167309-A1 Pharmaceutical Compounds CCNO, CDK2, CDK1 CDK14 38/4885CCNY 10/4885LMNA 655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.